HONG KONG – SK Biopharmaceuticals Co. Ltd., a spin-off from Korean conglomerate SK Holdings Co. Ltd., inked a joint research agreement with Twoxar Inc., a U.S.-based artificial intelligence (AI)-driven biopharma, to discover and develop drugs for non-small-cell lung cancer (NSCLC).